GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Genmab A/S (GMAB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term catalysts in 2026 and a strong pipeline, the current technical indicators, negative financial performance trends, and lack of immediate trading signals suggest holding off on buying right now. The investor may consider revisiting the stock closer to 2026 when catalysts materialize or if the stock shows stronger technical and financial performance.
The MACD is negatively expanding (-0.118), indicating bearish momentum. RSI is at 25.333, suggesting the stock is nearing oversold territory but not yet a clear buy signal. Moving averages are converging, showing no strong directional trend. The stock is trading near its support level (S1: 27.634), with resistance at 28.648. Overall, the technicals are weak, with no clear indication of a reversal.
Analysts expect 2026 to be a 'catalyst-rich' year with potential sales growth from Epkinly and petosemtamab. Multiple analysts maintain Buy ratings with price targets around $40-$48, indicating long-term optimism. The company's pipeline and acquisitions mitigate terminal value risk.
The stock has dropped 2.48% in regular trading and 1.28% in pre-market trading. Financial performance in Q4 2025 showed a significant decline in net income (-94.38% YoY) and EPS (-94.26% YoY), raising concerns about near-term profitability. No recent news or significant insider/hedge fund activity to support a near-term rally.
In Q4 2025, revenue increased by 14.63% YoY to $1.058 billion, but net income plummeted by 94.38% to $31 million. EPS also dropped by 94.26% to 0.49, and gross margin declined slightly to 92.34%. The financials show strong revenue growth but severe profitability challenges.
Analysts are generally bullish on GMAB, with multiple Buy ratings and price targets ranging from $38.50 to $48. However, there are concerns about near-term performance, as reflected in some lowered price targets. Analysts highlight 2026 as a pivotal year for the company, with multiple catalysts expected to drive growth.
